Regulus Therapeutics RGLS

Phio Pharmaceuticals Corp. (NASDAQ: $PHIO ) reported third quarter 2026 financial results and provided a business update as it advances PH-762 toward Phase 2b study initiation. Program milestones include completion of commercial-scale current Good Manufacturing Practice (cGMP) manufacturing, treatment in a long-term toxicology study, and submission of regulatory documents to the Food and Drug Administration (FDA). Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/phio-pharmaceuticals The business update, which follows completion of the PH-762 Phase 1b trial in June 2026, included: • The final clinical study report was submitted to FDA with a meeting request and briefing document covering the completed Phase 1b results and the planned Phase 2b neoadjuvant study in cutaneous squamous cell carcinoma, with a response expected by the end of November 2026 • Phio released its first commercial-scale cGMP batch of PH-762 drug substance, a milestone that supports the planned Phase 2b clinical program, which is expected to be initiated in the first quarter of 2027 • Phio's patent portfolio includes 56 issued patents and 34 pending applications worldwide, with additional pending applications extending potential protection into 2044 In the release, Phio's Chief Executive Officer commented on the quarter's manufacturing and regulatory milestones. "We have successfully executed on critical development objectives to advance the PH-762 program toward Phase 2b study initiation," said Robert J. Bitterman, President and Chief Executive Officer of Phio Pharmaceuticals. Read the full release: https://phiopharma.com/phio-pharmaceuticals-reports-third-quarter-2026-financial-results-and-business-update-as-it-advances-ph-762-toward-phase-2b-study-initiation/ Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical-stage biopharmaceutical company advancing its proprietary INTASYL® siRNA gene silencing technology to eliminate cancer. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical development program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) evaluated PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers. For additional information, visit the Company’s website, www.phiopharma.com. Discover more Featured Companies, Featured Experts, and upcoming Featured Conferences at b2idigital.com. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $RGLS, $AGEN, $XBI, $ARKG

$PHIO $ARWR $RGLS $AGEN $XBI $ARKG

$SCYX I'm out. I think they should stay focused on the antifungal space. Also, $RGLS was developing a treatment targeting the root cause of ADPKD, which looked promising and Novartis acquired them. I still have exposure to that drug through CVRs.

$SLS Get a kick out of the childish bro basher trying to say I missed out on $RGLS. I bought at $0.93 and made a massive profit when it got bought out. Oh, and how cute, I have $SLS on my post as well. Stop blind hating $SLS board. If you believe in the product, believe in the product. If you attack Bulls that have simple questions, you put off scammish vibes and raise more questions. $SLS doesn't need that right now. Do better.

TheRealShortSqueezy @TheShortSqueezy · 6s $ATAI: Recent News Strengthens Analyst Conviction ATAIBeckley is seeing increasing analyst conviction following the release of key clinical milestones and recent business developments. Latest Analyst Update: HC Wainwright & Co. has maintained its Buy rating on ATAI while raising its price target to $25.00 from $15.00, a 66.67% increase. Recent Analyst Coverage: Guggenheim – $11 price target (Jan 20, 2026) JonesTrading – $16 price target Canaccord Genuity – PT raised to $14 from $11 (+27%) Needham – $12 price target Institutional Activity: ARK Invest increased its position in Q4 2025 by 1,286,446 shares (+63.7%) ARK now holds 3,305,997 shares. Rising price targets, institutional buying, and continued execution reflect growing confidence in ATAIBeckley’s strategy and long-term potential. 📊 Communicated disclaimer: https://bit.ly/4ci8Ftu Sector Peers: $RLMD $SLS $ANIX $RGLS

$RLYB it's still tracking the $RGLS example (which got bought out a month after their data) within a few percentage points. RGLS was 1.40 pre-data....5 days after $2, two weeks later $4, and then a week later $8 buyout for a total of 4 weeks post-data. Next stops for us IMO, I assume news within Q1 (by March 31): $7 --> $10 --> $15 and then announcement (buyout / PIPE / partnership) --> $30+

$ATAI Delivers Major Development News🔬🧬 ATAI Life Sciences continues advancing its clinical pipeline following multiple recent milestones. Recent Key Milestones 🎯 The company has reported several important advancements across its pipeline and leadership: ➡️Positive Phase 2a topline results for EMP-01 in social anxiety disorder, providing early clinical proof-of-concept ➡️Continued development of core pipeline assets, including: 🥇BPL-003: progressing toward late-stage development 🥈VLS-01: currently in Phase 2 clinical trials ➡️Strengthened executive leadership with the appointment of a new Chief Financial Officer These developments highlight accelerating pipeline momentum heading into 2026 Investor Conferences 👇 🗓️March 4th: TD Cowen 46th Annual Health Care Conference 🗓️March 10th: Jefferies 2026 Biotech on the Beach 🗓️March 11th: Leerink Global Healthcare Conference Communicated Disclaimer : https://bit.ly/3OCJhol Sector Peers: $SLS $ANIX $RGLS $VNDA

$RLYB cont. from post below. 4). Data released Feb 14. Good efficacy and safety. Now company can talk again and is out of 'black period' . Now that they know plan going forward they can now share data with potential investors (PIPE theory) and/or suitors (parnter/buyout theory). Hence the 'clock' started on Feb 17. From Jan to Feb 17 they did not even know the future of their own company. Makes no sense that they would be sharing data w/ investors at this point. 5). Since data: Stock has rallied almost 50% . Constant buying pressure and volume pushing stock up to closer and closer to intrinsic value. Following the $RGLS example. Data , no reaction, then price adjustment. Then the buyout came for $RGLS a month later. Investors are just now seeing the data for the first time and a deal should take 30-60 days to complete. Expecting something soon . Price action seems to corroberate my theory as well. GLTA !